Aerocrine acquires all assets of U.S. competitor and ends litigation

Aerocrine acquires all assets of U.S. competitor and ends litigation

SOLNA, Sweden - 19 May 2010 - Aerocrine AB today announced that it has acquired
all business assets and intellectual property assets from the bankruptcy estate
of Apieron Inc.  As a result, Apieron's litigation against Aerocrine in the U.S.
and Germany will be terminated and dismissed.  Aerocrine's patent infringement
claims in the U.S. against Apieron's estate will not be dismissed, however.  

Following Apieron's launch in the U.S. of its Insight™ exhaled NO device in
2008, Aerocrine and Apieron have been engaged in patent litigation in the U.S
and Germany.  On March 30th 2010, referring to legal setbacks and lack of
financing, Apieron filed for Chapter 7 bankruptcy.  The bankruptcy court
appointed a trustee to administer the liquidation of Apieron's assets.  In an
auction held on May 12th in the United States Bankruptcy Court for the Northern
District of California, Aerocrine acquired the rights to all of Apieron's
business assets, including its portfolio of patents and trademarks. 

Due to small sales volumes and a manual process for the manufacturing of the
Insight exhaled NO device, Aerocrine will not invest to resume supply of the
Insight product that was discontinued by Apieron following its bankruptcy
filing. 


For more information, contact:  
Paul de Potocki, CEO Aerocrine AB, telephone: +46 8 629 07 80
Chip Neff, President Aerocrine Inc., telephone: +1 919 696 4267

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. The pioneer and leader
in the technology to monitor and manage airway inflammation, Aerocrine markets
NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable
measurement of airway inflammation and may thus play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on June 15th 2007.


Aerocrine discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 09:30 a.m. on May  19th 2010.